<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534962</url>
  </required_header>
  <id_info>
    <org_study_id>RAF-01</org_study_id>
    <secondary_id>2011-002789-18</secondary_id>
    <nct_id>NCT01534962</nct_id>
  </id_info>
  <brief_title>Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion</brief_title>
  <acronym>RAFFAELLO</acronym>
  <official_title>A Randomised, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging Phase II Study Assessing Ranolazine in the Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Non-permanent Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low,
      intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful
      electrical cardioversion in patients with persistent atrial fibrillation (AFib).

      After successful cardioversion and subsequent randomisation, patients report trans-telephonic
      EGCs on a daily basis to a central core ECG facility.

      Maximum treatment duration is 112 days (16 weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with persistent AFib are screened for eligibility and undergo direct current
      cardioversion (DCC). If DCC is successful (defined as persistence of sinus rhythm 2 h
      post-DCC) patients meeting all the inclusion criteria and none of the exclusion criteria are
      randomly assigned to the treatment arms (Ranolazine low, intermediate, high dose or placebo,
      given BID).

      Transtelephonic ECG devices (TT-ECG) are used for recording of AFib recurrence to be read by
      a Central ECG Core Laboratory. Any symptoms indicative of AFib have to be recorded by the
      patient in a diary.

      Study Visits are held for screening (Visit 1), at DCC and randomisation (Visit 2), one week
      post DCC (Visit 3), after 8 weeks of treatment (Visit 4), and at end of treatment (Visit 5).
      A safety follow-up telephone call is held 2 weeks after end of treatment.

      12-Lead ECGs are performed at every visit.

      Safety evaluations include regular safety laboratory blood and urine tests, 12-lead ECGs and
      the continuous recording of adverse events.

      A double-dummy technique is used to ensure double-blind conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Randomization to First Documented AF Recurrence.</measure>
    <time_frame>16 weeks (112 days)</time_frame>
    <description>Time to first AF recurrence reported by patient-reported TT-ECG or 12-Lead ECG at the study site, whichever occurred first.
Patients discontinuing the study without AF were censored at the time of the last available ECG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Documented AF Recurrences</measure>
    <time_frame>16 weeks (112 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to First Documented and Confirmed AF Recurrence</measure>
    <time_frame>16 weeks (112 days)</time_frame>
    <description>A confirmed AF recurrence was defined as a documented AF recurrence which was confirmed by a consecutive ECG performed at least 1 hour after first AF documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Documented and Confirmed AF Recurrences</measure>
    <time_frame>16 weeks (112 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion</measure>
    <time_frame>16 weeks (112 days)</time_frame>
    <description>Excluding patients with early relapses (within 48 hours) while the study drug, started after cardioversion, had not yet reached steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence</measure>
    <time_frame>16 weeks (112 days)</time_frame>
    <description>Documented AF recurrences in those patients who did not experience early relapses (within 48 hours after cardioversion)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Ranolazine low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine, low dose, oral, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine, intermediate dose, oral, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine, high dose, oral, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pill), oral, BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Oral administration, BID; for a maximum of 112 days.</description>
    <arm_group_label>Ranolazine low dose</arm_group_label>
    <other_name>Ranexa (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Oral administration, BID; for a maximum of 112 days.</description>
    <arm_group_label>Ranolazine intermediate dose</arm_group_label>
    <other_name>Ranexa (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Oral administration, BID; for a maximum of 112 days.</description>
    <arm_group_label>Ranolazin high dose</arm_group_label>
    <other_name>Ranexa (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, BID; for a maximum of 112 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years and older

          -  Patients with persistent AF suitable for electrical direct current cardioversion (DCC)

          -  A female of childbearing potential may be enrolled providing she has a negative
             pregnancy test at baseline and is routinely using an effective method of birth control
             resulting in a low failure rate until end of study

          -  Able to give written informed consent before any study related procedure

          -  Able to attend all the visits scheduled in the study

        Exclusion Criteria:

          -  Patients with first diagnosed AF or patients with paroxysmal AF

          -  Patients with long-standing persistent AF or permanent AF

          -  Patients having known concurrent temporary secondary causes of AF such as alcohol
             intoxication, pulmonary embolism, hyperthyroidism, pneumonia, hypoxemia, acute
             pericarditis or myocarditis

          -  Patients having undergone atrial catheter ablation for AF

          -  Patients carrying a pacemaker

          -  Patients with electrolytes imbalances that may cause cardiac arrhythmias, e.g.
             potassium &lt; 3.5 mmol/L or &gt; 5.5 mmol/L

          -  Patients with any contra-indications to Ranexa according to the drug-specific product
             characteristics

          -  Patients taking class I or Class III antiarrhythmic agents within 3 days of planned
             randomisation

          -  Patients taking beta-blockers unless used on stable doses for at least 2 weeks prior
             to the planned randomisation. Single doses of Intravenous beta-blockers are allowed up
             to 10 hours from the planned randomisation

          -  Patients taking Dronedarone or oral Amiodarone within 2 weeks and 3 months of planned
             randomisation, respectively

          -  Patients with a history of ECG abnormalities that in the opinion of the Investigator
             render the subject unsuitable for the trial, including history of congenital or a
             family history of long QT syndrome and a QTc interval ≥500 msec at Screening

          -  Patients with congestive heart failure NYHA grade III and IV;

          -  Patients with any serious intercurrent illness (including psychiatric and neurological
             disorders) which, in the opinion of the Investigator, is incompatible with the
             protocol.

          -  Patients taking Metformin at a total daily dose greater than 1000 mg.

          -  Patients taking Simvastatin at a total daily dose greater than 20 mg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J Camm, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Clinical Cardiology; St. Gerorge's University of London, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie</name>
      <address>
        <city>Goettingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS, Dip. Cardiotoracovascolare (U.C.C.)</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona, Servicio de Cardiología-Sección de Arritmias</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's University of London</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>July 29, 2014</results_first_submitted>
  <results_first_submitted_qc>July 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2014</results_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <keyword>Antiarrhythmic Agents</keyword>
  <keyword>Cardiac Electroversion</keyword>
  <keyword>Ranexa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 310 patients were screened and underwent cardioversion (CV). Of these, 241 were still in sinus rhythm 2 hours post-CV and, thus, were eligible for randomization.
Patients who experienced an atrial fibrillation (AF) recurrence could continue the study if no medical intervention was needed and otherwise had to discontinue the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine Low Dose</title>
          <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
        <group group_id="P2">
          <title>Ranolazine Intermediate Dose</title>
          <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
        <group group_id="P3">
          <title>Ranolazin High Dose</title>
          <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but did not start treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued at AF recurrence</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT-population (excluding 3 randomized patients who never started study drug)</population>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine Low Dose</title>
          <description>Ranolazine, low dose, oral, BID</description>
        </group>
        <group group_id="B2">
          <title>Ranolazine Intermediate Dose</title>
          <description>Ranolazine, intermediate dose, oral, BID</description>
        </group>
        <group group_id="B3">
          <title>Ranolazin High Dose</title>
          <description>Ranolazine, high dose, oral, BID</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo, oral, BID.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="11.8"/>
                    <measurement group_id="B2" value="65.5" spread="8.5"/>
                    <measurement group_id="B3" value="63.6" spread="11.3"/>
                    <measurement group_id="B4" value="65.2" spread="9.5"/>
                    <measurement group_id="B5" value="65.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since AF diagnosis</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="24.0"/>
                    <measurement group_id="B2" value="7.2" spread="12.9"/>
                    <measurement group_id="B3" value="15.5" spread="28.2"/>
                    <measurement group_id="B4" value="6.9" spread="13.5"/>
                    <measurement group_id="B5" value="10.0" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to First Documented AF Recurrence.</title>
        <description>Time to first AF recurrence reported by patient-reported TT-ECG or 12-Lead ECG at the study site, whichever occurred first.
Patients discontinuing the study without AF were censored at the time of the last available ECG.</description>
        <time_frame>16 weeks (112 days)</time_frame>
        <population>Intention-to-treat-approach that analyzed all randomised patients who took at least one dose of study medication (N=238, i.e. excluding 3 randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Low Dose</title>
            <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine Intermediate Dose</title>
            <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O3">
            <title>Ranolazin High Dose</title>
            <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to First Documented AF Recurrence.</title>
          <description>Time to first AF recurrence reported by patient-reported TT-ECG or 12-Lead ECG at the study site, whichever occurred first.
Patients discontinuing the study without AF were censored at the time of the last available ECG.</description>
          <population>Intention-to-treat-approach that analyzed all randomised patients who took at least one dose of study medication (N=238, i.e. excluding 3 randomized patients).</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" lower_limit="9.0">The upper limit of the CI was not calculable.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="68.0">The Kaplan-Meier estimate of the median was not calculable</measurement>
                    <measurement group_id="O3" value="117.0" lower_limit="17.0">The upper limit of the CI was not calculable.</measurement>
                    <measurement group_id="O4" value="58.0" lower_limit="16.0">The upper limit of the CI was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Documented AF Recurrences</title>
        <time_frame>16 weeks (112 days)</time_frame>
        <population>Intention-to-Treat (N=238)</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Low Dose</title>
            <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine Intermediate Dose</title>
            <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O3">
            <title>Ranolazin High Dose</title>
            <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Documented AF Recurrences</title>
          <population>Intention-to-Treat (N=238)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to First Documented and Confirmed AF Recurrence</title>
        <description>A confirmed AF recurrence was defined as a documented AF recurrence which was confirmed by a consecutive ECG performed at least 1 hour after first AF documentation.</description>
        <time_frame>16 weeks (112 days)</time_frame>
        <population>Intention-to-Treat (N=238)</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Low Dose</title>
            <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine Intermediate Dose</title>
            <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O3">
            <title>Ranolazin High Dose</title>
            <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to First Documented and Confirmed AF Recurrence</title>
          <description>A confirmed AF recurrence was defined as a documented AF recurrence which was confirmed by a consecutive ECG performed at least 1 hour after first AF documentation.</description>
          <population>Intention-to-Treat (N=238)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="11.0">The upper limit of the 95% CI was not calculable.</measurement>
                    <measurement group_id="O2" value="NA">The Kaplan-Meier estimate of the median and the lower/upper limit of the 95% CI was not calculable.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="117.0">The Kaplan-Meier estimate of the median and the upper limit of the 95% CI was not calculable.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="38.0">The Kaplan-Meier estimate of the median and the upper limit of the 95% CI was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Documented and Confirmed AF Recurrences</title>
        <time_frame>16 weeks (112 days)</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Low Dose</title>
            <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine Intermediate Dose</title>
            <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O3">
            <title>Ranolazin High Dose</title>
            <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Documented and Confirmed AF Recurrences</title>
          <population>Intention-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion</title>
        <description>Excluding patients with early relapses (within 48 hours) while the study drug, started after cardioversion, had not yet reached steady-state.</description>
        <time_frame>16 weeks (112 days)</time_frame>
        <population>Modified Intention-to-Treat Population (N=217) excluding 21 patients with AF relapse within 48 hours post cardioversion</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Low Dose</title>
            <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine Intermediate Dose</title>
            <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O3">
            <title>Ranolazin High Dose</title>
            <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion</title>
          <description>Excluding patients with early relapses (within 48 hours) while the study drug, started after cardioversion, had not yet reached steady-state.</description>
          <population>Modified Intention-to-Treat Population (N=217) excluding 21 patients with AF relapse within 48 hours post cardioversion</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="11.0">The upper limit of the 95% CI was not calculable.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="98.0">The Kaplan-Meier estimate of the median and the upper limit of the 95% CI was not calculable.</measurement>
                    <measurement group_id="O3" value="117.0" lower_limit="18.0">The upper limit of the 95% CI was not calculable.</measurement>
                    <measurement group_id="O4" value="78.0" lower_limit="37.0">The upper limit of the 95% CI was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence</title>
        <description>Documented AF recurrences in those patients who did not experience early relapses (within 48 hours after cardioversion)</description>
        <time_frame>16 weeks (112 days)</time_frame>
        <population>Modified Intention-to-Treat Population (N=217) excluding 21 patients with AF relapse within 48 hours post cardioversion</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Low Dose</title>
            <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O2">
            <title>Ranolazine Intermediate Dose</title>
            <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O3">
            <title>Ranolazin High Dose</title>
            <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence</title>
          <description>Documented AF recurrences in those patients who did not experience early relapses (within 48 hours after cardioversion)</description>
          <population>Modified Intention-to-Treat Population (N=217) excluding 21 patients with AF relapse within 48 hours post cardioversion</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks (112 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine Low Dose</title>
          <description>Ranolazine, low dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
        <group group_id="E2">
          <title>Ranolazine Intermediate Dose</title>
          <description>Ranolazine, intermediate dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
        <group group_id="E3">
          <title>Ranolazin High Dose</title>
          <description>Ranolazine, high dose, oral, BID
Ranolazine: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo (sugar pill), oral, BID.
Placebo: Oral administration, BID; for a maximum of 112 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="65"/>
                <counts group_id="E2" events="33" subjects_affected="24" subjects_at_risk="60"/>
                <counts group_id="E3" events="27" subjects_affected="23" subjects_at_risk="58"/>
                <counts group_id="E4" events="28" subjects_affected="27" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E3" events="19" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Most of the Kaplan-Meier estimates could not be calculated due to the lower than expected number of observed events and the high variability of data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Angela Capriati MD PhD, Head of Corporate Clinical Research</name_or_title>
      <organization>Menarini Ricerche S.p.A</organization>
      <phone>00390555680 ext 9933</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

